Category Archives: Business and Investments

Latest From Business and Investments

Nasdaq Social Bell: Twitter Strategies For Biotechs

Nasdaq Social Bell

Last week at the BIO CEO & Investor Conference in New York City, I had the pleasure of speaking with John Machiz and Brad Smith from Nasdaq at their headquarters in Times Square to discuss the social media activity that happened onsite during the event, what made the discussion of the event online so robust, and what biotech companies can do to increase their visibility on Twitter. View the video below, and get a recap of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Deal Structures: More Options for Companies

CEO2013_115x75_Thumbnail copy

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Ten Years of Therapeutic Venture Capital


What therapeutic areas have received the most funding in private drug companies over the last decade? How much of this has been for new drugs vs drug delivery? How much into biologics vs small molecules? This week, we released a first-of-its-kind, comprehensive report on venture capital trends covering 2004-2013. To investigate investor trends in specific therapeutic areas and level of innovation, we analyzed data from four venture capital databases to create the broadest, most comprehensive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Dow Jones VentureWire: BIO Report on Venture Funding for Therapeutic Innovation


Today, Brian Gormley’s story – Biotech VCs Shift Away From Chronic Diseases, Report Says – highlights VC funding trends over a 10-year period. BIO released the report today showing that venture capital is shifting away from chronic diseases and increasing for rare diseases. The report categorized $38 billion of investment across more than 1,200 companies from 2004 through 2013. BIO’s report compares five-year periods before and after the financial crisis. From 2004 through 2008, for Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?


Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several of the arguments frequently made in recent debates about the price and value of innovative medicines. Philipson argues that physicians are often self-interested as buyers when complaining about drug prices, and often fail to understand the broader economic context in which drug pricing decisions must be made: “Just as you wouldn’t let a financial planner perform cancer surgery, we shouldn’t Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,